Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alzheimer Disease (AD): early-phase trial registry
3 of 6 indexed Alzheimer Disease (AD) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Alzheimer Disease (AD): 6 US clinical trials tracked, 3 recruiting.
Alzheimer Disease (AD) is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Qure Healthcare, running 1 of these trials.
Enrollment posture brief
Registry condition alzheimer-disease-ad
OPEN 3 | RECR 50% | LATE 0 | EARLY 2 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Achalasia (50% recruiting · 8 trials)
Alzheimer Disease (AD) lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Alzheimer Disease (AD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Alzheimer Disease (AD) is recruiting above its size-band peers.
3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Alzheimer Disease (AD) research.
Qure Healthcare accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Alzheimer Disease (AD) enrolment sits around 200 participants.
Median target enrolment is 200 among the 6 trials that report a genuine target (sentinel values excluded). 2 of those (33.3%) plan for fewer than 100 participants.
-
Alzheimer Disease (AD) splits between interventional and observational designs.
4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
HudsonAlpha Institute for Biotechnology
NCT07146412
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
Ashvattha Therapeutics
NCT05395624
Brain NAD in Alzheimer's Disease
Florida Atlantic University
NCT07127510
Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)
Marymount University
NCT07180147
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
Eli Lilly and Company
NCT03518073
Establishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assay
Qure Healthcare
NCT07099001
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Alzheimer Disease (AD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Alzheimer Disease (AD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Alzheimer Disease (AD) page
6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Alzheimer Disease (AD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Qure Healthcare sponsors the most Alzheimer Disease (AD) trials on record, review their full trial history before evaluating a specific study. See Qure Healthcare's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alzheimer Disease (AD) condition card totals 6 registered trials; most-linked intervention Alzheimer's disease assay results; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.